ANXA13

Across TCGA pan-cancer cohorts, ANXA13 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANXA13 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ANXA13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANXA13 expression acts as an unfavorable survival marker, although some lineages such as COAD and HNSC show a favorable association.

COAD, HNSC, and UCEC are the cancer types where ANXA13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	III,IV	1.000	0.844	.044	12	view →
HNSC	OS	Quartile	All	0.846	0.471	.024	2	view →
UCEC	DFS	Median	All	0.960	0.761	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANXA13–COAD (DFS)

Open the COAD breakdown →